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PROTEIN ARUHAN IN-VIVO Leptospira DAN APLIKASINYA DALAM 
PEMBANGUNAN UJIAN PENGESANAN ANTIBODI DAN ANTIGEN 
UNTUK PENYAKIT LEPTOSPIROSIS AKUT 
 
 
ABSTRAK 
 
Leptospirosis yang disebabkan oleh Leptospira spp. patogenik merupakan 
ancaman kesihatan sedunia yang muncul semula. Justeru, adalah penting untuk 
mengenalpasti penanda diagnostik baru dan menyelidik potensi penggunaannya dalam 
asai pengesanan antibodi dan antigen bagi diagnosis leptospirosis akut. Dengan 
menggunakan panel sampel serum daripada leptospirosis fasa akut (Kumpulan I) dan 
campuran (Kumpulan II), kajian ini dimulakan dengan menilai prestasi dua kit 
diagnostik pantas leptospirosis, iaitu Leptorapide dan VISITECT-LEPTO, yang lazim 
digunakan di Malaysia. Kedua-dua kit ujian tersebut menunjukkan sensitiviti 
diagnostik yang rendah (≤34%) terhadap sampel serum fasa akut, tetapi sensitiviti 
yang lebih baik terhadap sampel fasa campuran. Sampel serum yang terpilih dari 
Kumpulan I digunakan untuk mengenalpasti penanda diagnostik baru daripada  
perpustakaan ekspresi DNA genomik Leptospira dengan menggunakan teknologi 
antigen aruhan in-vivo (IVIAT). Klon faj S8A1 telah dikenalpasti dan pecahan gen-
nya (dinamakan sebagai LepS8A1FL) telah diklonkan ke dalam plasmid rekombinan. 
Protein tersebut seterusnya diekspres dalam sistem ekspresi protein Escherichia coli 
dan ditulen dengan menggunakan “Immobilized Metal Affinity Chromatography”. 
Dua terbitan terpenggal LepS8A1FL (dinamakan sebagai LepS8A124 and 
LepS8A134) dan penanda-penanda diagnostik leptospirosis yang pernah dilaporkan 
(dinamakan sebagai LigA, LipL41, OmpL1 dan LipL32) turut dihasilkan dengan 
kaedah yang ternyata di atas. Dalam blot western Immunoglobulin M (IgM), 
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LepS8A1FL menunjukkan prestasi yang memuaskan dengan sensitiviti dan spesifisiti 
75%. Ia mengungguli LipL41 dan LigA yang pernah dilapor dalam mengesan 
leptospirosis akut. Walau bagaimanapun, protein tersebut menunjukkan nilai 
diagnostik sederhana dalam format asai “Enzyme-Linked Immunosorbent” (ELISA) 
IgM. Satu asai dipstik aliran sisi (LFD) IgM yang menggunakan LepS8A1FL 
seterusnya telah dibangunkan, dan masing-masing menunjukkan sensitiviti dan 
spesifisiti diagnostik sebanyak 65.7% dan 63.2%. Kajian ini diteruskan dengan ujian 
pengesanan antigen untuk leptospirosis akut. Untuk tujuan ini, antibodi poliklonal 
arnab terhadap pecahan sel kasar Leptospira dan kesemua protein rekombinan 
leptospiral tersebut telah dihasilkan. Asai LFD yang menggunakan antibodi anti-
pecahan leptospiral sebagai kedua-dua antibodi tangkapan dan antibodi berkonjugat 
emas mengungguli kombinasi antibodi yang lain. Ia menunjukkan limit pengesanan 
yang tinggi, spesifisiti yang baik serta reaktiviti yang luas. Ujian tersebut menunjukkan 
sensitiviti dan spesifisiti diagnostik masing-masing 57.4% dan 87.2%. Ujian 
pengesanan antigen tersebut juga mengesan antigen leptospiral di dalam air kencing 
manusia. Di samping itu, dengan menggabungkan keputusan ELISA IgM LepS8A1FL 
dan asai LFD pengesanan antigen tersebut, sensitiviti diagnostik 86.2%  dan spesifisiti 
diagnostik 73.7% tercapai. Secara kesimpulannya, kedua-dua ujian pengesanan 
antibodi dan antigen dalam kajian ini patut dibangunkan selanjutnya untuk digunakan 
dalam diagnosis leptospirosis akut pada manusia. 
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LEPTOSPIRAL PROTEINS INDUCED IN-VIVO AND ITS APPLICATION 
IN THE DEVELOPMENT OF ANTIBODY AND ANTIGEN DETECTION 
TESTS FOR ACUTE LEPTOSPIROSIS 
 
 
ABSTRACT 
 
Leptospirosis, caused by pathogenic Leptospira spp., is a re-emerging global 
health threat. Therefore, it is pertinent to identify novel diagnostic marker and 
investigate its potential use in antibody and antigen detection assays for detection of 
acute leptospirosis. Using panels of serum samples from acute (Group I) and mixed 
(Group II) phase leptospirosis, the present study was initiated by evaluating 
performance of two leptospirosis rapid diagnostic kits, namely Leptorapide and 
VISITECT-LEPTO, that were commonly used in Malaysia. Both test kits showed low 
diagnostic sensitivity (≤34%) with the acute phase serum samples, but better 
sensitivity with the mixed phase samples. Selected serum samples from Group I were 
used to identify novel diagnostic marker(s) from Leptospira genomic DNA expression 
library using In-vivo Induced Antigen Technology. A phage clone, S8A1, was 
identified and its gene fragment (named as LepS8A1FL) was cloned into recombinant 
plasmids. The protein was then expressed in Escherichia coli protein expression 
system and purified using Immobilized Metal Affinity Chromatography. Two 
truncated derivatives of the LepS8A1FL (namely LepS8A124 and LepS8A134) and 
previously reported diagnostic markers for leptospirosis (namely LigA, LipL41, 
OmpL1 and LipL32) were produced with the methods described above. In 
Immunoglobulin M (IgM) western blot, LepS8A1FL showed a satisfactory 
performance with 75.0% sensitivity and specificity. It outperformed the reported 
LipL41 and LigA in detecting acute leptospirosis. In an IgM Enzyme-Linked 
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Immunosorbent Assay (ELISA) format, the protein, however, has moderate diagnostic 
value. An IgM lateral flow dipstick assay (LFD) using LepS8A1FL was subsequently 
developed and demonstrated diagnostic sensitivity and specificity of 65.7% and 
63.2%, respectively. The present study also pursued an antigen detection test for acute 
leptospirosis. For this purpose, rabbit polyclonal antibodies against Leptospira crude 
cell lysate and all of the above leptospiral recombinant proteins were produced. The 
LFD assay which used anti-leptospiral lysate antibody as both immobilized and gold-
labelled antibody was superior to other antibody combinations. It showed high limit of 
detection, good specificity and broad reactivity. The test demonstrated diagnostic 
sensitivity and specificity of 57.4% and 87.2%, respectively. The antigen detection test 
also detected leptospiral antigen in human urine. Meanwhile, by combining the results 
of LepS8A1FL IgM ELISA and the antigen detection LFD test, a diagnostic sensitivity 
of 86.2% and diagnostic specificity of 73.7% was achieved. In conclusion, both 
antibody and antigen detection tests in this study merit further development for use in 
diagnosing acute leptospirosis in human. 
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1.0 Introduction 
Leptospirosis is a bacterial infection caused by pathogenic species of Leptospira. The 
disease is most prevalent in tropical regions because of the warm and high humidity 
atmosphere (Picardeau, 2013). The pathogen may potentially infect all mammals, 
including human. Depending on the animals and the infecting serovars, the disease 
may cause a wide range of manifestation to animals, including asymptomatic, acute, 
chronic symptoms and carrier stage (Jobbins and Alexander, 2015; Adler, 2014). Upon 
acquiring the infection, the chronic-infected or carrier animals can further contaminate 
the surrounding environment by passing urine containing the bacteria into soil and 
fresh water streams. Thus, other potential hosts who live in the epidemic area may be 
exposed to the bacteria and further propagate the disease (Subharat et al., 2011).  
Human is an accidental host for the pathogen. Leptospirosis cases are estimated 
to be approximately one million and 58,900 deaths per annum (Costa et al., 2015). 
This represents 14.77 cases and 0.84 deaths per 100,000 population, respectively. 
Human-to-human transmission is practically non-existent. The disease is transmitted 
to human upon contact with water contaminated by animal hosts as described above. 
The bacteria enters human body via the breached skins and mucous membranes 
(Picardeau, 2017). Four major risk factors expose human to pathogenic Leptospira: i) 
recreational water activities, ii) watery-associated occupations e.g. paddy and poultry 
farmers as well as workers in slaughterhouse, iii) post-natural disasters e.g. flood and 
typhoon, and iv) poor hygiene.  
 Leptospirosis is a biphasic disease (Gasem et al., 2009). Following an 
incubation period of 5-14 days, a patient is in acute (leptospiraemic) phase and 
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develops symptoms such as high fever, headache and myalgia, which are similar to 
other febrile illnesses such as dengue and malaria. If left untreated, the pathogen may 
infect vital organs during convalescent phase and cause mortality to a patient. 
Nevertheless, the disease can be treated effectively by administrating appropriate 
antibiotic regimen (Phimda et al., 2007). Hence, a good clinical management highly 
depends on correct identification of the disease. Due to unspecific clinical symptoms 
of acute leptospirosis, laboratory diagnosis become a critical tool to detect the disease 
and further support clinical decision of a suspected patient (McBride et al., 2007). 
Many diagnostic tools to detect anti-leptospiral antibody are readily available in the 
market. However, there is a big room to improve leptospirosis diagnosis because 
performance of most kits are poor in detecting acute phase of leptospirosis due to the 
absence or low anti-leptospiral antibody in the early disease stage (Bajani et al., 2003). 
 Currently, most of the serological tests for leptospirosis used crude cell proteins 
from the non-pathogenic L. biflexa as the antigens. The strategy is relatively 
straightforward and convenient for manufacturers. However, one of its major 
drawback is its inconsistency of diagnostic performance in different countries. This is 
because the predominant Leptospira serovar varies between countries. As a result, the 
anti-leptospiral antibody developed by a patient, which is serovar specific, may not be 
efficiently detected by those serological tests (Blacksell et al., 2006). To overcome this 
limitation, it is necessary to identify diagnostic marker(s) that is conserved across 
different Leptospira serovars. To date, several protein antigens, such as LipL21, 
LipL32 and LipL41 have been identified (Natarajaseenivasan et al., 2008; Boonyod et 
al., 2005; Cullen et al., 2003). Yet, their performance differs particularly in detecting 
the IgM antibody in acute leptospirosis sera (Toyokawa et al., 2011). As such, new 
approaches should be implemented to identify novel antigenic markers for 
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serodiagnosis of leptospirosis. It is known that bacterial proteins which are highly 
expressed during infection event (also known as in vivo induced proteins) may be 
incorporated into diagnostic tool as antigens to detect the antibodies raised in a patient 
(Cao et al., 2004). In Vivo Induced Antigen Technology (IVIAT) is a method to 
identify these diagnostic markers by immunoscreening genomic or complementary 
DNA library of a particular microorganism without the need to use an animal model 
(Hu et al., 2014). The technology facilitates identification of immunogenic leptospiral 
protein antigens that are expressed during infection event. Previously, IVIAT has been 
used to discover novel diagnostic markers from several pathogens such as 
Mycobacterium tuberculosis, Vibrio cholera and Bacillus anthracis (Kumar et al., 
2011; Rollins et al., 2008; Hang et al., 2003). Based on the results of the above studies, 
IVIAT-identified protein(s) may be useful for IgM detection of leptospirosis in human.     
 On the other hand, it is known that leptospiral antigens are circulating in a 
leptospirosis patient during acute phase (Picardeau, 2013). Thence, detection of the 
circulating antigens demonstrates direct evidence of acute leptospirosis. Unlike IgM 
detection tests, antigen detection test is not in the market. As a result, the current study 
pursues this approach by using antibodies to selected leptospiral antigens, such as 
LigA, LipL32, LipL41 and OmpL1, since these proteins are reported to be abundant 
in the bacteria (Malmstrom et al., 2009). In addition to that, this study was also 
designed to detect whole cell antigens of Leptospira spp. as an approach to include 
undefined circulating leptospiral antigens. This antigen detection strategy may 
complement with antibody detection test described above for improved diagnosis of 
acute leptospirosis in human.  
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2.0 Literature Review 
 
2.1 World Epidemiology 
Due to Leptospira spp. preference to proliferate in hot and wet atmosphere, majority 
of leptospirosis incidence occurred in tropical countries located between tropic of 
Capricorn and Cancer (Figure 2.1). In tropical countries, its annual incidence rate 
exceeds 10 cases/100,000 population which was higher than the reported 0.1-1 
case/100,000 population in temperate climates (Picardeau, 2013). Highest morbidity 
rate was reported at Oceania (150.68/100,000 population), followed by South East 
Asia (55.54/100,000 population), Caribbean (50.68/100,000) and East Sub-Saharan 
Africa region (25.65/100,000) (Costa et al., 2015). Of note, small tropical countries or 
islands in these regions are highly endemic for leptospirosis. A work by Pappas et al. 
(2008) revealed Seychelles (43.2/100,000 population) to be the country in the world 
with highest incidence rate, followed by Trinidad and Tobago (12.0/100,000 
population) and Barbados (10.0/100,000 population). However, the actual prevalence 
might be more serious than those reported because data from developing countries are 
normally under-estimated and less reliable (Pappas et al., 2008). Considering low 
socioeconomic status of the regions, the disease might be under-recognized as a 
potential public health threat (Schneider et al., 2013). In addition to that, long heavy 
rainfall season in tropical climate further promotes the disease incidence (Ko et al., 
1999). 
CHAPTER TWO 
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Figure 2.1 Distribution and leptospirosis burden illustrated in Disability Adjusted Life Years (DALYs)/100,000 population per year. One 
DALYs unit represents one year which a healthy individual lost due to a circumstance, e.g. disease and disability. Reprinted from Torgerson, P. 
R., et al. (2015).  
 
Tropic of Cancer 
Tropic of Capricorn 
Equator 
6 
2.1.1 Leptospirosis in Malaysia 
Leptospirosis is an endemic disease in Malaysia. The first recorded human 
leptospirosis study in Malaysia was performed on rural inhabitants and rubber 
plantation workers  by Fletcher (1928). As an endemic country for leptospirosis, the 
average morbidity rate was estimated to range between 1-10/100,000 population (Lim, 
2011). Figure 2.2 illustrates trends of leptospirosis incidence and death cases for the 
past 11 years. A nine-year study (2004-2012) conducted by Benacer et al. (2016) 
demonstrated an average annual incidence rate of 4.83/100,000 population. However, 
the annual incidence rate markedly increased year to year, noting from 0.97 (2004) to 
12.47 (2012) cases/100,000 population throughout the study. Abdul Wahab (2015) 
reported that the highest leptospirosis incidence rate (25.5 cases/100,000 populations) 
and mortality cases (92 cases) in Malaysia occurred in 2014. A spiked increase over 
60% of cases reported compared to its preceding year has been linked to heavy rainfall 
and flood that happened in many states of Malaysia during the year (Garba et al., 
2017). Continuous increase in reported leptospirosis cases was correlated to the fact 
that leptospirosis was instated as a national notifiable disease since 9th December 2010 
under Prevention and Control of Infectious Disease Act 1988. Following year, an 
official guideline by Ministry of Health (MOH) Malaysia regarding diagnosis, 
management, prevention and control of the disease was published.  These approaches 
commit better surveillance and monitoring by health institution and government. 
Particularly, it raises awareness of the disease among clinical practitioners, which 
contributed to better prognosis and early treatment initiation to the suspected patients. 
In Malaysia, male gender constituted 78.7% of total leptospirosis cases in 
between 2004-2012 (Benacer et al., 2016). This contributed a male-to-female ratio of 
3.69:1. The phenomenon of male outnumbered female patients is common in
7 
 
 
 
 
 
Figure 2.2 Trends on leptospirosis incidence and death cases in Malaysia between 
2004 to July 2015. Data adapted from Abdul Wahab (2015). 
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leptospirosis worldwide and has been associated with high risk occupation and 
recreational activities predominated by male (Costa et al., 2014; Felzemburgh et al., 
2014). Malaysian patient demography reported the mean (±SD) age of leptospirosis 
patients was 33.79 (±17.55) and median of 31 years old (Benacer et al., 2016). 
Malaysian within age group of 30-39 years old has the highest morbidity rate (16.21 
cases/100,000 population). Constitution of age group 30-39 years old as the major 
group for leptospirosis was similarly observed in different epidemiological settings 
(Costa et al., 2015; Goris et al., 2013a). Compared to school children and adolescent, 
it was predicted that middle age adult possessed more mobility which lead to higher 
exposure risk to the disease (Benacer et al., 2016).  
Leptospirosis risk is frequently present during rainfall and flood season in 
developing countries, whereas water recreational activities are more relevant in 
developed countries (Mwachui et al., 2015). In Malaysia, annual reported leptospirosis 
cases similarly follow the seasonality pattern. A spiked case number was reported in 
October-March in peninsular Malaysia and in October-February in east Malaysia 
(Benacer et al., 2016). This is in concordance with wet season in the country. 
Weinberger et al. (2014) claimed that rainfall flush the Leptospira spp. bacteria which 
typically survive in wet soils into water bodies. As such, human at watery grounds is 
more prone to the infection. However, excessive volume of rainfall provides dilution 
effect to the bacteria load, which inversely present as a protective factor to the flood 
victim (Suwanpakdee et al., 2015).  
Thayaparan et al. (2015) demonstrated a seroprevalence of 35.9% among 
villagers (n=198) in periurban area of Kuching, Sarawak. Villagers who work around 
forest and involve in national service exhibit seroprevalence of more than 50%. 
Meanwhile, plantation workers in Johor and Melaka recorded a seroprevalence of 
9 
28.6% (Janudin et al., 2016). Leptospira serovar Lepto 175 Sarawak was the 
predominant serovar in these oil palm plantations, contributing to 62% among the 
seropositive workers (Janudin et al., 2016). A cross-sectional study of leptospirosis 
seroprevalence among 999 febrile patients in ten Kelantan government hospitals 
showed higher leptospirosis seroprevalence among patients from high-risk 
occupational group, e.g. outdoor worker, agriculture worker and military  (Rafizah et 
al., 2013a). In addition to that, Rafizah et al. (2013b) reported that patient with 
exposure to recreational activity has 2.4 times higher risk for leptospirosis.  
 
2.1.2 Outbreaks and Case Reports in Malaysia 
As an endemic country, leptospirosis outbreaks happen intermittently in Malaysia. The 
most recent scientific literature about leptospirosis outbreak in Malaysia was dated 
2012. Leptospirosis outbreak was reported in Pauh, Perlis among family members after 
fisheries activity at a swamp in Kampung Padang Telela (Baharudin et al., 2012). The 
swamp was an abandoned paddy field and has been neglected for long time. After 
approximately two weeks, eight out of 28 of the participants involved showing 
common febrile symptoms such as fever, headache, vomiting and muscle pain. 
Serology test for the presence of leptospiral IgM using immunochromatographic test 
(VISITECT-LEPTO, Omega-Diagnostic, UK) demonstrated six samples to be 
positive. Most of the samples were then further confirmed to be positive by MAT 
and/or Polymerase Chain Reaction (PCR) at Institute for Medical Research (IMR) 
Malaysia. Pathogenic Leptospira spp. DNA was identified in seven out of eight water 
samples from the swamp. Hence, the incident was categorized as a point-source 
outbreak. 
10 
On 26th June 2010, a search and rescue operation on a drowned young man was 
conducted in Lubuk Yu, Pahang. Lubuk Yu is a recreational forest with river and 
waterfall. Among 153 people who participated the rescue, 21 of them developed fever 
≥ 38oC seven days post-operation (IQR 1-13 days) (Sapian et al., 2012). Ten serum 
samples of the patients were cultured-positive for Burkholderia pseudomallei. Out of 
which four serum samples were positive for leptospirosis by PCR, suggesting co-
infection with Leptospira spp. High fatality rate of 38% (8/21) was reported in this 
outbreak. In detail, fatality rate for melioidosis alone and melioidosis-leptospirosis co-
infection were 66.7% (4 out of 6) and 75% (3 out of 4), respectively. All water samples 
(n=6) and two out of four soil samples collected on site of operation showed positive 
for Leptospira spp. This has been linked to heavy rainfall during first two days of the 
operation which might flush the bacteria onto the soil surface and into the river. 
The first international leptospirosis outbreak happened in Sabah (Sejvar et al., 
2003). During 21st August to 1st September 2000, a number of 304 athletes participated 
in Eco-Challenge Sabah multisport endurance race. Fifteen days (range one to 24 days) 
after the race, 80 out of 189 athletes showed common febrile symptoms, including 
fever, headache, chills, diarrhea and muscle aches. In addition to that, 40 athletes 
showed conjunctival suffusion which is a representative symptom for leptospirosis. A 
total of 29 case-patients were admitted to hospital. All the patients recovered and no 
death case was reported. Serological test showed positive reaction in 68% (26/38) of 
the serum samples. Multivariate stepwise logistic regression demonstrated that 
swimming in Segama River is the main risk factor contributed to this point-source 
outbreak. Abrasions and cuts on the athletes in jungle trekking preceding to swimming 
in the river increased the risk of exposure to Leptospira spp.  
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2.2 Classification and Typing of Leptospira  
2.2.1 Taxonomy 
Leptospires belong to family Leptospiraceae in the phylum of Spirochetes. The 
phylum members consisted of mammalian pathogens which cause a vast array of 
serious diseases, particularly in human. Besides leptospirosis, some notorious human 
diseases caused by the spirochetes members are syphilis (Treponema pallidum), Lyme 
disease (B. burgdorferi), relapsing fever (Borrelia spp.), yaws (T. pallidum subsp. 
Pertenue), pinta (T. carateum) and periodontal disease (Treponema spp.). In general, 
spiral shapes and endoflagella motility are the hallmarks of spirochetes. They 
demonstrated morphology of long, thin bacteria with flat-waves, helices or irregular 
shape under the microscope (Wolgemuth, 2015).  These special modes of propulsion 
and morphology indeed represents virulence factors of spirochetes. However, in year 
2012 a novel genus, namely Sphaerochaeta, was included as a member of phylum 
Spirochaetes (Caro-Quintero et al., 2012). It implies an exception to the morphology 
hallmark of spirochetes as the species are non-motile and sphere in shape. 
The Leptospiraceae family was defined in 1979 to initially cover genera 
Leptonema as well as Leptospira. A decade ago, Levette et al. (2005) transferred 
Leptospira parva to genus Turneriella as Turneriella parva, contributing three genera 
under the family. The three genera were characterized by divergences in GC content 
%, 16S rRNA gene sequences and DNA-DNA relatedness (Adler, 2015). GC content% 
within members of Leptospiraceae ranged from 35 to 54 mol%. Leptospira 
demonstrated the lowest ratio of 35-41 mol%  (Ko et al., 2009). Leptonema has a GC 
content% of 54 mol%, while Turneriella has the largest ratio of 53.6% mol%.  
The type genus is defined as Leptospira Noguchi in the honor of Noguchi 
(1917) who proposed the genus name after studying the pathogen isolates from USA, 
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Japan and Europe. The type species is L. interrogans (Stimson, 1907) Wenyon 1926. 
Since 1980, the type strain has been designated as serovar icterohaemorrhagiae RGAT 
strain (ATCC 43642) as per enlisted in Approved Lists of Bacterial Names (Skerman 
et al., 1980).  
 
2.2.2 Classification of Leptospira Species And Subspecies 
Three distinct classifications were used for Leptospira species, namely serology, 
genetic and phylogeny classification. While these classifications methods have little 
relatedness between each other, they present advantages and disadvantages that 
appropriately suit the aim of a particular study.  
Since 1914, rapid isolation of the bacteria happened throughout different 
location of the world. Following proposal of “Leptospira” as the genus name, a number 
of species names have been assigned based on serological typing, such as the outcome 
of cross-agglutinin absorption test and difference in antigenicity of the bacteria. 
Examples of Leptospira species defined by the serological typings are L. canicola, L. 
hebdomadis, L. icterohaemorrhagiae and L. biflexa (Robinson, 1948). Considering 
inappropriate assignation of species name based on serological classification, Wolff 
and Broom (1954) proposed to use “serovar” for naming of serologically distinct 
strains. Following that, the bacteria strains were divided into two Leptospira species, 
namely L. icterohaemorrhagiae and L. biflexa, comprising all pathogenic and 
saprophytic strains, respectively. The name for pathogenic strain was then amended to 
L. interrogans (Wolff and Turner, 1963). To date, there are more than 250 serovars 
have been identified for Leptospira spp., which were grouped into 24 serogroups 
(Levett, 2001). Classification based on Leptospira serovars is widely used in 
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epidemiological and clinical setting. Yet, it has no relevance to the bacteria taxonomy.  
In Malaysia, the three most common pathogenic Leptospira serovars are L. interrogans 
serovar Australis, Birkini and L. borgpetersenii serovar Javanica (Fairuz Amran, 
personal communication). 
Methods above classifies pathogenic and non-pathogenic Leptospira into two 
species, namely L. interrogans and L. biflexa, respectively. With advance in genomic 
study, the members in the two Leptospira species were found to have low DNA 
homology, suggesting there are more species that laid within L. interrogans and L. 
biflexa categorized using the above methods (Haapala et al., 1969). Thus, DNA-DNA 
hybridization technique has been widely used in many studies to characterize species 
within genus Leptospira. A total of 21 species have been identified to date. With the 
advance in molecular and analytical technique, several methods which are faster and 
more reliable have been prompted for species identification. For instance, MALDI-
TOF has been adopted to identify Leptospira species in a recent study (Rettinger et al., 
2012). Multilocus sequence typing has also been demonstrated to be able to identify 
the species similar to that of DNA-DNA hybridization (Boonsilp et al., 2013). It is 
expected that next generation sequencing will be the future trend for species 
identification. 
By analyzing 16S rRNA and housekeeping genes such as gyrB and rrs, the 
Leptospira species mentioned above can be further categorized in a phylogenetic tree 
based on its pathogenicity (Picardeau, 2017; Morey et al., 2006; Slack et al., 2006). 
As illustrated in  Figure 2.3, a phylogenetic tree can be constructed into three major 
clades, following pathogenic, intermediate and saprophytic characteristic of the 
bacteria. The pathogenic Leptospira comprised species that have been characterized 
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Figure 2.3 Phylogenetic analysis of Leptospira spp. 16S rRNA and classification 
of Leptospira based on its pathogenicity. Reprinted from Picardeau (2017) with 
permission from Springer Nature.  
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to cause human and animal leptospirosis. On the contrary, species in saprophytic clade 
are free-living and have never demonstrated evidences in infecting a host. The 
intermediate Leptospira may occasionally cause leptospirosis with mild symptoms in 
human and animal host.     
 
2.3 Animal Reservoir for Pathogenic Leptospira spp. 
Leptospirosis has been claimed as the most common zoonotic disease. All mammals, 
including bats and pinnipeds, can virtually be hosts for the pathogenic bacteria 
(Picardeau, 2017). Unlike human who is an accidental host, leptospirosis in animal is 
either in asymptomatic, acute, chronic or acute-to-chronic stage with persistent 
bacteria carriage and excretion into the environment for a duration varies between 
species. As a consequence, this amplifies the infection within the ecosystem and 
engenders leptospirosis risk to human and animal surrounding.  
Rodent is well known to be the main reservoir for Leptospira spp. and plays an 
important role in transmitting the disease to human and animals. As a natural reservoir, 
rat did not show any symptom upon infection. Although systemic infection occurs in 
the early stage, the bacteria is rapidly clear from blood and most organs of rats 
(Athanazio et al., 2008). The rat acts as a chronic carrier because the bacteria remain 
colonizes proximal tubules of kidney and being continuously shed into environment 
via urine. With bacterial load as high as 107/mL, an area may be seriously 
contaminated following repeating urination as the virulent leptospire is highly viable 
in surface water, stream, river or moist soil for weeks to months (Monahan et al., 
2008).  
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Domestic animals likewise impose leptospirosis risk to human as well as 
surrounding environment. However, these domestic animals show different degree of 
symptoms upon infected. Dogs demonstrate clinical presentation most resemble to 
human leptospirosis. Canine leptospirosis may lead to life-threatening with febrile 
illness symptoms in addition to vascular, liver and kidney damage (Pijnacker et al., 
2016). Stray dogs transmit pathogenic Leptospira spp. from wild and natural 
environment close proximity to human; domestic dogs put human at the risk of 
contamination by shedding the bacteria in household environment (Hua et al., 2016; 
Gay et al., 2014).  
Staying in the same farm, livestock acquires the disease from infected herd 
mates and rodents that shed urine into the soil and water (Subharat et al., 2011). Since 
basic necessity needs (food, water, refuge) are available ad libitum in farm, it becomes 
a habitat for wildlife reservoirs to stay close to livestock (de Oca et al., 2017). The 
factors above expose workers at livestock farm to occupational-acquired leptospirosis. 
Besides as a health threat to the workers, leptospirosis is associated with economic 
impact in livestock sector particularly with goats, sheep, pigs and cattle. In general, 
the infected livestock may suffer from reproduction disorders (Rizzo et al., 2017; 
Ramos et al., 2006). Meanwhile, recurrent uveitis, as a result of autoimmune response 
between ocular tissue and leptospiral membrane proteins, is a hallmark for equine 
leptospirosis (Verma et al., 2013). Even though the disease is of veterinary 
significance, Garba et al. (2017) claimed a lack in livestock leptospirosis studies. In 
fact, inter-species transmission of the disease between sheep and cattle has been 
demonstrated in a herd two decades ago, suggesting presence of leptospirosis among 
livestock in Malaysia (Bahaman, 1991).  
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Despite similarity in genetic, Leptospira serovars show characteristic 
preferences to specific animal reservoir. Icterohaemorrhagiae and Ballum serogroup 
are usually predominated in rats and mice, respectively (Bharti et al., 2003). Although 
not absolute, serovar Canicola in dogs, Harjo in cattle Pomona in pigs as well as 
Bratislava in horses have been primarily demonstrated (Schuller et al., 2015; Gamage 
et al., 2014; Andre-Fontaine, 2006; Grooms, 2006). Ellis (2010) reported that dog is 
the only maintenance host for serovar Canicola. Molecular background which 
contributes a serovar to host specificity is unknown. Frequently, these serovars do not 
cause severe manifestation in their highly-adapted reservoir hosts (Bharti et al., 2003). 
These serovars, on the other hand, may cause severe clinical outcome to other 
incidental hosts.  
 
2.4 Anatomy of Leptospira 
The genus name, Leptospira, derives from Greek leptos (thin) and Latin spira (coiled). 
The bacteria is a thin spirochete with approximate diameter of 0.15 µm and length of 
6-20 µm. The organism is easily distinguishable from other bacteria due to their 
distinctive morphology of thin, right-handed helix coil and is highly motile. 
Frequently, at least one end of the bacteria bends into hook which resemble a question-
mark, thus contributing to the species name interrogans (“interrogate”, ask question). 
Morphology of Leptospira spp. is shown in Figure 2.4. 
 
2.4.1 Lipopolysaccharide 
As illustrated in Figure 2.5A, Leptospira spp. has a Gram negative-like cell wall. The 
outer membrane consists of many surface exposed outer membrane (OM) proteins, 
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Figure 2.4 Morphology of Leptospira interrogans. (A) Demonstration of 
characteristic hook end of the bacteria. (B) Visualization wave body shape of the 
bacteria by scanning electron microscopy at 3000x. (C) Measurement of the bacterial 
cell and relative length of its endoflagellum to the cell length. (D) Schematic diagram 
of the bacterial cell wall. Reprinted from Bharti et al. (2003) and Picardeau (2017) 
with permission from Elsevier and Nature Publishing Group, respectively.
D 
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Figure 2.5 Schematic diagram of Leptospira spp. cell wall. (A) Illustration of the 
bacterial cell wall architecture. It consists of outer and inner membrane, spaced by 
periplasm with contains endoflagellum. Lipopolysaccharide, lipoprotein, outer- and 
transmembrane proteins are abundantly located at the outer membrane, while several 
transport systems are located within inner membrane layer. (B) Schematic structure of 
lipopolysaccharide. It consists of repetitive O-antigen and Lipid A, linked by a core 
oligosaccharide region. Reprinted from Raja and Natarajaseenivasan (2015) and 
Erridge et al. (2002) with permission from Elsevier. 
Outer 
membrane 
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membrane 
Periplasm 
Polysaccharide 
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lipoproteins as well as lipopolysaccharide (LPS). While LPS constitutes the major 
component of Leptospira spp. OM, it is absent from other spirochetal pathogens such 
as B. burgdorferi and T. pallidum (Ren et al., 2003).  The LPS of Leptospira spp. 
consists of three components which are associated to each other via covalent linkage 
(Figure 2.5B): i) hydrophobic lipid A that protrudes from the bacteria OM, ii) O 
antigen side chain that highly exposes to the environment and iii) oligosaccharide 
macromolecules that join the lipid A and O antigen together (Patra et al., 2015). It is 
generally known that LPS oligosaccharide composition and orientation are different 
among Leptospira. As a consequence, this characteristic contributes to classification 
of Leptospira serovars and serogroups (Adler, 2015). Patra et al. (2015) reported that 
the pathogenic serovar LPS is much more complex and possessed molecular mass 
higher than the intermediate serovar. 
The LPS plays a different role in triggering innate immune response between 
human and murine. It activates TLR1 and TLR2 receptor in human but TLR2 and 
TLR4 in murine (Vaure and Liu, 2014). Inability of human TLR4 to recognize the 
leptospiral LPS could be an escape mechanism of Leptospira from being recognized 
by the human innate immune system. This lead to a delayed immune response in 
human, resulting an overwhelming and probably lethal infection by the pathogenic 
Leptospira spp (Nahori et al., 2005). Besides that, due to variation of LPS structure in 
different Leptospira serovars, monovalent LPS vaccine tends to provide protection 
against homologous infection, but partial or absence of protection against heterologous 
infection in a vaccinated animal (Wang et al., 2007; Bulach et al., 2000; Sonrier et al., 
2000). In the course of leptospirosis, the LPS appears to be the predominant antigen in 
triggering agglutination antibodies of a patient during convalescent phase of infection 
(Adler, 2015; Guerreiro et al., 2001).  
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2.4.2  Outer Membrane Proteins 
Right beneath leptospiral LPS is the outer membrane layer consisting of abundant OM 
proteins (Figure 2.5). Contrary to LPS, the leptospiral OM proteins are principally 
conserved across all species members of Leptospira (Cullen et al., 2005). For this 
reason, OM proteins are thought to be good antigen target for diagnosis of leptospirosis 
as it overcomes serovar-specificity disadvantage of LPS. Lipoproteins are proteins 
with N-terminal signal peptide which undergo post-translational modification with 
fatty acid moiety after the signal peptide was removed. In Leptospira spp., LipL32 
protein is the most abundant OM protein with ~38,000 copies of molecules per cell 
occupying ~20% of leptospiral OM inner surface (Malmstrom et al., 2009). This is 
followed by peptidoglycan associated cytoplasmic membrane protein (30,389 
copies/cell), LipL36 (14,100 copies/cell) and LipL41 (10,531 copies/cell) (Malmstrom 
et al., 2009).  
The LipL32 is only conserved in pathogenic and intermediate species of 
Leptospira, but no evidence showed that it is important for OM integrity nor infection 
(Kumaran et al., 2017). The lipoprotein may interact with host blood proteins such as 
fibronectin, plasminogen, collagen XX and laminin A5 (Chaemchuen et al., 2011; 
Vieira et al., 2010). Collectively, the host proteins serve as a masking layer to protect 
the bacteria cell surface assessable by immune proteins.  
Even though LipL36 is conserved in infectious Leptospira spp., evidences 
demonstrated that LipL36 is down-regulated in vivo (Barnett et al., 1999). This 
downregulation could be related to change in environment as lipL36 gene of L. 
interrogans serovar Copenhageni was shown to be downregulated at 37oC and in the 
presence of sodium chloride at physiologic osmolarity (Matsunaga et al., 2007; Nally 
et al., 2001b).  
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The third abundant lipoprotein, LipL41, however, demonstrated opposite 
characteristic. While it is conserved among pathogenic Leptospira spp., its level 
remained constant throughout different osmolarity and temperature studied to date, nor 
it is essential for acute leptospirosis event and trigger inflammation (King et al., 2013; 
Matsunaga et al., 2007; Yang et al., 2006; Nally et al., 2001b). For this reason, the 
lipoprotein has been used as a loading control in immunoblot application (Matsunaga 
et al., 2013). Recently, LipL41 has been shown to form a 36-mer macromolecule with 
heme-binding ability, suggesting it to be involved in iron acquisition and metabolism 
(Lin et al., 2013).  
 
2.4.3 Periplasm 
Periplasm of Leptospira spp. contains a thin peptidoglycan layer, a 
glycosaminopeptide polymer that assemble into exoskeleton and determine helical 
shape of the bacteria.  As shown in Figure 2.5A, the peptidoglycan of Leptospira is 
unique as it is closely associated with the inner (cytoplasmic) membrane raher than the 
OM as in the cases for most of Gram-negative bacteria (Raddi et al., 2012). The 
distinctive characteristic contributes low stability and high fluidity to OM of 
Leptospira (Tang et al., 2014). On the other hand, Slamti et al. (2011) reported helical 
shape in the purified Leptospira peptidoglycan saccule. This leads to a conclusion that 
the peptidoglycan layer, together with other cytoskeleton proteins, play primary role 
in determining helical morphology of the bacteria. 
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2.4.4 Endoflagellum 
The leptospiral endoflagellum (also known as periplasmic flagellum) presents as a 
vital component for corkscrew mobility of Leptospira. Similar to the other spirochetes, 
the leptospiral endoflagellum is located in periplasm. One tightly-coiled endoflagellum 
is situated near each termini of Leptospira and extends towards center of the cells 
without overlapping with the endoflagellum from the other ends (Wolgemuth, 2015).  
Motility of Leptospira has been related to rotation direction of the 
endoflagellum (Wolgemuth et al., 2006). Clockwise and anti-clockwise rotation of the 
endoflagellum leads to formation of hook- and spiral-shaped ends, respectively (Raddi 
et al., 2012). As illustrated in Figure 2.6, translational motility occurs when spiral-
shaped end is formed at the anterior while hook-shaped end is present at the posterior. 
Such asymmetric shape generates forward thrust that facilitates the bacteria to “swim” 
(Wolgemuth, 2015). On the contrary, a leptospiral cell rotating on the ground has 
hook- or spiral-shape at both ends (Wolgemuth, 2015). Interestingly, swimming 
direction of the bacteria has been observed to be transited as fast as hundred 
miliseconds facilitated by rapid reversal in the motor rotation direction (Kan and 
Wolgemuth, 2007; Goldstein and Charon, 1990). 
 
2.5 Pathogenesis 
Leptospirosis is a zoonotic disease transmitted to human via direct or indirect contact 
with pathogenic Leptospira spp. Human-to-human transmission are practically non-
existence. Frequently, the bacteria gain entrance into the victim body via mucous 
membrane or cuts on the skin when exposed to leptospiral-contaminated medium such
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Figure 2.6 Illustration of leptospiral motility. The bacteria rapidly change its ends 
according to the need for translocation due to rotation of the endoflagellum. When one 
end is in spiral and the other end is in hook shape, the bacteria gain motility towards 
the direction of spiral shape. Nonetheless, the bacteria does not translocate when both 
end of the cell are in the same shape. Reprinted from Wolgemuth (2015) with 
permission from Elsevier. 
